0
Articles |

A Comparison of Double-Strength Beclomethasone Dipropionate (84 µg) MDI With Beclomethasone Dipropionate (42 µg) MDI in the Treatment of Asthma

Robert A. Nathan; Keith B. Nolop; Francis M. Cuss; Richard R. Lorber
Author and Funding Information

Affiliations: From the University of Colorado Health Sciences Center, Denver,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia

Affiliations: From the University of Colorado Health Sciences Center, Denver,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia

Affiliations: From the University of Colorado Health Sciences Center, Denver,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ,  From the Asthma and Allergy Associates, Colorado Springs; Schering-Plough Research Institute, Kenilworth, NJ; Thomas Jefferson Medical College, Philadelphia


1997 by the American College of Chest Physicians


Chest. 1997;112(1):34-39. doi:10.1378/chest.112.1.34
Text Size: A A A
Published online

Abstract

Study objective: To compare the efficacy and safety of a double-strength formulation of beclomethasone dipropionate (BDP 84) metered-dose inhaler (MDI) with that of beclomethasone dipropionate (BDP 42) MDI in the treatment of chronic asthma.

Design: A 28-day, randomized, double-blind, double-dummy, placebo-controlled, multicenter study.

Setting: Outpatient.

Patients: A total of 423 patients aged 12 to 65 years (mean range, 34 to 36 years) with moderate asthma (FEV1, 50 to 80% of predicted) who required long-term inhaled corticosteroids were enrolled.

Interventions: Patients were randomized to receive BDP 84, two oral inhalations bid (336 µg/d), BDP 42, four oral inhalations bid (336 µg/d), or placebo. A fourth treatment arm administering BDP 84, eight oral inhalations bid (HD BDP 84; 1,344 µg/d) was also included to determine whether a dose-response relationship could be demonstrated.

Measurements: Spirometry, clinical observations.

Results: The three active treatments were significantly more effective (p≤0.01) than placebo at all time points in improving FEV1, the primary efficacy parameter; BDP 42 and BDP 84 were comparable to each other at every time point. Secondary pulmonary function tests (FVC, forced expiratory flow at 25 to 75% of FVC, and peak expiratory flow rate) showed similar results. All three active treatments were well tolerated. A dose response between 336 µg/d and 1,344 µg/d was demonstrated.

Conclusion: In this well-controlled 28-day study, BDP 42 and BDP 84 were shown to be comparable in efficacy and safety on a microgram-for-microgram basis.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543